03/06/23 4:01 PMNasdaq : CHRS Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results– Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENYCA ® autoinjector approved by FDA; UDENYCA ® on-body injector under review by FDA – – Planning underway for potentialRHEA-AIneutral
03/06/23 8:00 AMNasdaq : CHRS fda approvalFDA Approves UDENYCA® Autoinjector- UDENYCA ® is the only pegfilgrastim therapy delivered in a convenient, easy-to-administer prefilled autoinjector to offer in-clinic and at-home administration options for cancer patients undergoing myelosuppressive chemotherapy - - An additional presentation, the UDENYCA ® proprietary on-bodyRHEA-AIpositive
03/01/23 8:25 AMNasdaq : CHRS conferencesCoherus BioSciences to Present at Upcoming Investor Conferences in MarchCoherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March. 43rd Annual Cowen Health Care Conference on Tuesday, March 7 th at 2:10 p.m. ET BarclaysRHEA-AIneutral
02/28/23 8:25 AMNasdaq : CHRS conferencesearningsCoherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus’RHEA-AIneutral
02/15/23 8:25 AMNasdaq : CHRS clinical trialCoherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal CarcinomaShanghai Junshi Biosciences Co., LtdRHEA-AIvery positive
02/13/23 8:25 AMNasdaq : CHRS Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid ServicesCoherusRHEA-AIpositive
02/03/23 5:30 PMNasdaq : CHRS Coherus BioSciences Announces New Employment Inducement GrantsCoherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 sharesRHEA-AIvery positive
01/09/23 8:20 AMNasdaq : CHRS acquisitionCoherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge BiopharmaCoherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with KlingeRHEA-AIvery positive
01/04/23 7:01 AMNasdaq : CHRS conferencesCoherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare ConferenceCoherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentationRHEA-AIneutral
12/24/22 12:01 AMNasdaq : CHRS Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions with the FDA to support the inspections and gain approval of toripalimab for patients with NPC inRHEA-AIvery positive